DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rahman, Afia Tasnim | ko |
dc.contributor.author | Shin, Jongoh | ko |
dc.contributor.author | Whang, Chang-Hee | ko |
dc.contributor.author | Jung, Wonsik | ko |
dc.contributor.author | Yoo, Dohyun | ko |
dc.contributor.author | Seo, Changjin | ko |
dc.contributor.author | Cho, Byung-Kwan | ko |
dc.contributor.author | Jon, Sangyong | ko |
dc.date.accessioned | 2023-07-04T01:01:03Z | - |
dc.date.available | 2023-07-04T01:01:03Z | - |
dc.date.created | 2023-07-03 | - |
dc.date.created | 2023-07-03 | - |
dc.date.issued | 2023-05 | - |
dc.identifier.citation | ACS NANO, v.17, no.11, pp.10996 - 11013 | - |
dc.identifier.issn | 1936-0851 | - |
dc.identifier.uri | http://hdl.handle.net/10203/310225 | - |
dc.description.abstract | Inflammatory bowel disease (IBD) manifests as intestinalbarrierdestruction, mucosal immunity dysregulation, and disrupted gut microbiomehomeostasis. Conventional anti-inflammatory medications for IBD therapypartially alleviate symptoms but are unable to restore normal barrierand immune function. Here, we report a nanomedicine comprising bilirubin(BR)-attached low-molecular-weight, water-soluble chitosan nanoparticles(LMWC-BRNPs), that promotes restoration of the intestinal barrier,mucosal immunity, and the gut microbiome, thereby exerting robusttherapeutic efficacy. In a mouse model of dextran sulfate sodium salt(DSS)-induced colitis, orally administered LMWC-BRNPs were retainedin the GI tract much longer than other nonmucoadhesive BRNPs owingto the mucoadhesiveness of LMWC via electrostatic interaction. Treatmentwith LMWC-BRNPs led to considerable recovery of the damaged intestinalbarrier compared with the current IBD medication, 5-aminosalicylicacid (5-ASA). Orally administered LMWC-BRNPs were taken up by pro-inflammatorymacrophages and inhibited their activity. They also concurrently increasedthe population of regulatory T cells, thereby leading to the recoveryof dysregulated mucosal immunity. An analysis of the gut microbiomerevealed that LMWC-BRNPs treatment significantly attenuated the increase Turicibacter, an inflammation-related microorganism, resultingin protection of gut microbiome homeostasis. Taken together, our findingsindicate that LMWC-BRNPs restored normal functions of the intestineand have high potential for use as a nanomedicine for IBD therapy. | - |
dc.language | English | - |
dc.publisher | AMER CHEMICAL SOC | - |
dc.title | Bilirubin Nanomedicine Rescues Intestinal Barrier Destruction and Restores Mucosal Immunity in Colitis | - |
dc.type | Article | - |
dc.identifier.wosid | 001006767700001 | - |
dc.identifier.scopusid | 2-s2.0-85162225416 | - |
dc.type.rims | ART | - |
dc.citation.volume | 17 | - |
dc.citation.issue | 11 | - |
dc.citation.beginningpage | 10996 | - |
dc.citation.endingpage | 11013 | - |
dc.citation.publicationname | ACS NANO | - |
dc.identifier.doi | 10.1021/acsnano.3c03252 | - |
dc.contributor.localauthor | Cho, Byung-Kwan | - |
dc.contributor.localauthor | Jon, Sangyong | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | Bilirubin | - |
dc.subject.keywordAuthor | Bilirubin nanoparticles | - |
dc.subject.keywordAuthor | Low-molecular-weightchitosan | - |
dc.subject.keywordAuthor | Inflammatory bowel disease | - |
dc.subject.keywordAuthor | Oral delivery | - |
dc.subject.keywordPlus | INFLAMMATORY-BOWEL-DISEASE | - |
dc.subject.keywordPlus | DSS-INDUCED COLITIS | - |
dc.subject.keywordPlus | CONJUGATED CHITOSAN | - |
dc.subject.keywordPlus | ULCERATIVE-COLITIS | - |
dc.subject.keywordPlus | ORAL DELIVERY | - |
dc.subject.keywordPlus | NANOPARTICLES | - |
dc.subject.keywordPlus | MICROBIOTA | - |
dc.subject.keywordPlus | MICE | - |
dc.subject.keywordPlus | PLATFORM | - |
dc.subject.keywordPlus | MODELS | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.